Log in
Research; date; attribution:
Since 2005, EaStCHEM research expertise in electrochemistry and in sensing and detection, in partnership with University of Edinburgh researchers and expertise from the associated disciplines of medicine, engineering and physics and funded by the Scottish Intermediary Technology Institute (now Scottish Enterprise, SE) has formed a multidisciplinary team and developed the research outputs and novel platform technologies with enhanced detection characteristics (sensitivity, specificity, ability to handle clinical samples, rapid time-to-result) applicable to point-of-care diagnosis of wound infection state.
Significance: This technology was exclusively licensed from SE by Mölnlycke Health Care AB in 2012. Mölnlycke Health Care AB also established a new subsidiary, MHC Scotland Ltd in the BioQuarter in Edinburgh, to develop this technology, marking their entry into the multibillion dollar global point of care diagnostics market, as well as employing 5 UoE researchers.
Reach: Mölnlycke Health Care AB is a leading innovator in infection control in hospitals having ~7000 employees worldwide and with manufacturing plants in 9 countries.
Beneficiaries: The impact deriving from the underpinning research is to Mölnlycke Health Care AB as evidenced by formation of a significant new business venture and alteration of business practice, through the adoption and commercialisation of our new technology platform and the employment of 5 UoE staff from the research programme as human capital in MHC Scotland Ltd.
Hagan Bayley's research on nanopore sensing for DNA sequencing at the University of Oxford led to the formation of the spin-out company Oxford Nanopore Technologies Ltd (ONT) in 2005. Since 2008, ONT has raised £ 97.8M to support research and product development. This level of investment arises as a direct result of the pioneering technology ONT has developed, based on research in the UOA, which has the potential to revolutionise DNA sequencing and other single molecule analyses. ONT currently employs 145 people, nearly six times as many as in 2008, and was recently valued at $ 2 billion. Evidence from ONT was used in a 2009 House of Lords report on genomic medicine, demonstrating ONT's position at the forefront of this new technology.
UCL research has been instrumental in creating critically needed new biocatalysts and bioprocess technologies for industrial biocatalytic process development. These have impact across the UK chemical and pharmaceutical sectors. BiCE enzyme technologies have been exploited through the formation of a spin-out company, Synthace, generating investment of £1.8m and creation of 7 new jobs. Commercial utilisation of BiCE enzymes by company partners has led to environmental benefits through sustainable syntheses and reduced waste generation. BiCE high-throughput bioprocess technologies have also been adopted to speed biocatalytic process development. UCL established a parallel miniature stirred bioreactor system as a new product line for HEL Ltd. [text removed for publication]. Related knowledge transfer activities have also benefited some 157 industrial employees from over 50 companies since 2008.
Diffusion bonding (DB) is well-known for producing structured materials with fine scale features and is a critical technology for high efficiency reactors, e.g. heat exchangers and fuel cells, but currently equipment is slow and expensive (and there are size limitations to the `assemblies' that can be built). The University has researched and developed, with industry partners, a rapid affordable diffusion bonding (ADB) process involving direct heating to provide appropriate temperature and stress states and utilising flexible ultra-insulation (vacuum) for pressing titanium (and now aluminium) sheets together. The process operates at low stresses thus avoiding `channel' collapse. Investment is taking place in the partner companies to exploit the technology. A breakthrough has been achieved in the chemical machining of three dimensional structures for laminar flow technology assemblies in aluminium and titanium, that can be built by ADB.
This case study outlines the impact in generating investment in a spin-out SME and in developing a technology for clinical diagnosis based on chemistry research carried out in Bath. The research led to a spin-out company, Atlas Genetics, which has raised over £18M funding in the REF period specifically to develop the Atlas io™ platform, novel technology for rapid (<30 minute) and robust detection of infectious diseases suitable for point-of-care. The investment has created new jobs for highly skilled workers at the cutting-edge of medical diagnostics, with Atlas currently employing 36 staff. The io™ platform has been fully developed and has undergone successful clinical tests on multiple infections (based on bespoke Chemistry developed at Bath) prior to clinical trialling and rollout in Europe and the United States.
Practical Waveform Engineering, developed at Cardiff, is having a major impact on how modern- day microwave power amplifiers are designed, delivering real competitive advantages for global communications companies such as Nokia-Siemens-Networks and M/A-COM.
Economic impact is through reduced time-to-market and lower design costs, leading to high- performance power amplifier products. Examples include $40M revenue and employment of additional staff for M/A-Com, and the successful spin-off company Mesuro Ltd., generating revenue in excess of £2.5M.
Impact on practice is through successful demonstration of new device technologies and amplifier architectures, the introduction of PWE-based CAD models, and most significantly, the introduction of the "Cardiff Model" into mainstream simulation tools.
Environmental Impact is by improving the efficiency of power amplifiers and significantly reducing the carbon contribution of mobile communications systems, translating into savings of approximately £2.5M/year and a 17 kiloton reduction in CO2 emission for a typical EU network.
In recognising the challenges facing a competitive, globalised pharmaceutical industry, the Advanced Bioprocessing Centre team at Brunel University have pioneered the technology and a methodology for speeding up the R&D, purification and manufacture of new drugs.
Already being adopted by market leading pharmaceutical companies, the High Performance Counter-current Chromatography presents a new technological platform to generate significant reductions in development costs; an increase in yield and a greener waste process.
The research supported by eight Research Councils grants totalling £3,557,168 led to establishing a spin-out company, Dynamic Extractions, which today operates a commercial enterprise with £1M turnover in partnership with Brunel.
High-throughput genotyping has revolutionised the genome-wide search for associations between genetic variants and disease. Professor Sir Edwin Southern of the University of Oxford's Biochemistry Department invented the highly cost-effective array-based method of analysing genetic variation based on hybridisation between probes and samples on glass slides or `chips'. The spin-out company Oxford Gene Technology (OGT) founded by Southern in 1995 licenses the patent to manufacturers of `single nucleotide polymorphism (SNP) chips', including Illumina and Agilent, a global business exceeding $500M per year. Southern has continued to refine and extend this technology to increase its speed, efficiency and cost-effectiveness. This revolutionary technology has widespread applications such as prediction of individual risk, development of new drugs, provision of personalised treatments, and increased cost-effectiveness of clinical trials. Licence revenues fund R&D within OGT, and endow charitable trusts supporting primary school science education in the UK and crop improvement in the developing world.
Economic impact is claimed through the growth of the biopharmaceutical spin-out company Q Chip Ltd. During the REF period, this has created 19 new jobs, £7.5M investment, a new Dutch subsidiary (Q Chip BV), and staged-payment, six figure contract sales to four major international pharmaceutical companies.
Q Chip has generated over £928K in contract sales from the pharmaceutical industry from 2008-2012, with further sales of over £1M projected in 2013-14.
Originally established by Professor David Barrow in 2003 from his micro technology research, Q Chip has developed new processes and miniaturised equipment to encapsulate materials, including drugs, within uniform polymeric microspheres as injectable therapeutics.
As 288,000 UK construction workers were estimated to have contracted vibration white finger and 170,000 had claimed compensation by 2011 this study relates to the design and development of a hand and arm vibration (HAVmeter) monitor by the ERPE Reactec student start-up company. This company initially focussed on optimisation of sweeping for curlers, contributing to team GB winning the 2002 Winter Olympic Gold medal. The current Reactec (HAVmeter) instrument measures and reports on vibration white finger, which potentially affects 5 million British workers.
The HAVmeter has sales in excess of £9M, over the 2008-2013 period, and is now in use by 45,000 construction workers. Reactec, with 23 employees and a turnover of ~£2.5M p.a., company innovation has been recognised with 4 industrial awards since 2009.